Daily Remedy

Empowering patients, Educating the public
Health News & Discussions🧑‍⚕️
Find us at

[Daily Remedy @TheDailyRemedy]

Longevity medicine is a field in the process of inventing itself — assembling, from the raw material of geroscience, a clinical practice that has outpaced both its evidence base and its regulatory framework. https://t.co/JskqqOgEVQ

[Daily Remedy @TheDailyRemedy]

The SELECT trial's results, published in 2023, established something that the GLP-1 agonist's mechanistic profile had long suggested but clinical evidence had not yet confirmed: https://t.co/elO1sKlV1n

[Daily Remedy @TheDailyRemedy]

The traditional employer pharmacy benefit structure — select a PBM, sign a contract, delegate formulary management — has not disappeared. https://t.co/9MPTpHWBzE

[Daily Remedy @TheDailyRemedy]

Mark Cuban's Cost Plus Drugs launched in January 2022 with a proposition simple enough to be disruptive: https://t.co/VPiTgxRF6Y

[Daily Remedy @TheDailyRemedy]

The legal framework for ERISA fiduciary duty does not distinguish between retirement plans and health plans. https://t.co/SzsKK9vqoy

[Daily Remedy @TheDailyRemedy]

The self-insured employer is, in theory, the most sophisticated buyer in American healthcare. It bears the full financial risk of its employees https://t.co/FygnTlpVv4

[Daily Remedy @TheDailyRemedy]

Every system generates the consultants it deserves. The pharmaceutical rebate system https://t.co/O8RNZoSw8B

[Daily Remedy @TheDailyRemedy]

The Medicaid best price rule is an elegant policy mechanism with an unintended consequence that has become inseparable from its intended effect. https://t.co/Q7dO7FdjV0

[Daily Remedy @TheDailyRemedy]

The idea is simple enough to fit on an index card: instead of manufacturer rebates flowing to pharmacy benefit managers and plan sponsors at the end of a contract period https://t.co/1NLobGkbO8

[Daily Remedy @TheDailyRemedy]

Call it the rebate wall: the financial barrier that branded pharmaceutical manufacturers have erected around their formulary positions, https://t.co/YqWCmhiilN

[Daily Remedy @TheDailyRemedy]

There is a category error embedded in most comparisons of MedPricer and Turquoise Health https://t.co/uEnBICh0Lw

[Daily Remedy @TheDailyRemedy]

The request-for-proposal processes that large health plans run for analytics vendors share a recurring structural problem https://t.co/TsDSX5mjbw

[Daily Remedy @TheDailyRemedy]

Two platforms, two theories of change. That is the cleanest way to frame a comparison between MedPricer and Turquoise Health that resists the temptation to rank them as competitors on a single dimension. https://t.co/wn71eSoG6B

[Daily Remedy @TheDailyRemedy]

Knowing the terrain and navigating it are different skills — a distinction cartographers have understood for centuries and healthcare market reformers have spent decades obscuring. https://t.co/aEXpOQ9mSW

[Daily Remedy @TheDailyRemedy]

The machine-readable files arrived on schedule, and almost nobody knew what to do with them. https://t.co/IdkEadjCVp

[Daily Remedy @TheDailyRemedy]

When the FDA declared the semaglutide shortage resolved in February 2025 and the tirzepatide shortage resolved in October 2024, https://t.co/PD3nYfmF1m

[Daily Remedy @TheDailyRemedy]

Casgevy and Lyfgenia, the two FDA-approved gene therapies for sickle cell disease, list at $2.2 million and $3.1 million respectively, administered once. https://t.co/DV2VnvZFYo

[Daily Remedy @TheDailyRemedy]

Ask a pharmaceutical executive what their drug costs, and the answer you receive will depend on what the executive wants you to know . https://t.co/1lv6Jl1B5k

[Daily Remedy @TheDailyRemedy]

Most organizations that consume drug pricing data never question it. https://t.co/qsswkDzAx4

[Daily Remedy @TheDailyRemedy]

If a single legislative paragraph could expose the rebate that flows from a manufacturer to a plan sponsor through a pharmacy benefit manager, . https://t.co/nfueVB4KKv